Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Alia Therapeutics logo — On-target gene therapies

Alia Therapeutics

On-target gene therapies

Founded 2018 Italy Italy 15 employees Seed Total: $5.70M Biotechnology, Health and Wellness

General Information

Company Name Alia Therapeutics
Founded Year 2018
Location Italy Italy +2
Employees 15
Industries Biotechnology, Health and Wellness
Funding Stage Seed
Social

Get notified when Alia Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Alia Therapeutics

Alia Therapeutics is a biotechnology startup based in Italy, founded in 2018, which has recently attracted a significant €4.40M investment in a Seed Round at 17 April 2023. This investment was led by Sofinnova Partners, Indaco Venture Partners, and BiovelocITA. The company is focused on developing on-target gene therapies using novel CRISPR systems, aiming to revolutionize medicine by addressing genetic diseases at their roots. With a versatile portfolio of CRISPR systems, Alia is expanding the range of targetable genomic sites and increasing the precision of genetic modifications. This enables the company to take gene editing to a new level of specificity and safety, crucial for therapeutic applications. Alia Therapeutics is positioned at the forefront of the rapidly evolving gene editing and biotechnology fields, making it a compelling prospect for potential investors.

Taxonomy: Gene therapy, CRISPR, Genome editing, Genetic diseases, Rare diseases, Therapeutic approaches, Italian biotech, Biomedical technology, Genetic medicine, Incurable diseases

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 3
Investor Investor
•••• •••• 		17 Apr 2023
Seed Round •••••• 1
Investor
30 Jun 2021
Seed Round •••••• 2
Investor
•••• •••• 		08 Apr 2019

Alia Therapeutics Alternatives & Competitors

Alia Therapeutics vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care
Alia Therapeutics vs
LogicBio Therapeutics
LogicBio Therapeutics United States

Develops gene therapy vectors for previously incurable genetic and infectious diseases including hem...

Acquired
13 employees
Biotechnology
Alia Therapeutics vs
GenEditBio Limited
GenEditBio Limited Hong Kong S.a.r.

A biotech startup company aiming to provide potentially curative gene editing-based solutions for ge...

Seed
18 employees
Biotechnology

FAQ About Alia Therapeutics

On-target gene therapies
Alia Therapeutics was founded in 2018.
Alia Therapeutics is headquartered in Italy.
Alia Therapeutics operates in the following industries: Biotechnology, Health and Wellness.
Alia Therapeutics has approximately 15 employees.
Alia Therapeutics has completed 3 funding rounds, raising a total of $5.70M. The latest funding stage is Seed.
Top alternatives and competitors to Alia Therapeutics include Modalis Therapeutics, LogicBio Therapeutics, GenEditBio Limited, EmendoBio, Prime Medicine, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alia Therapeutics and Modalis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Alia Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy